2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.30 (Poster) Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors

PP01.30 (Poster) Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors

Back to course

Pdf Summary

A study was conducted to integrate molecular cancer classification and Next-Generation Sequencing (NGS) to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses who may be eligible for KRAS inhibitors. KRAS inhibitors have recently been approved by the FDA for certain types of non-small cell lung cancer (NSCLC) with a specific KRAS mutation. The current eligibility criteria for KRAS inhibitor treatment require both identification of the tissue of origin and confirmation of the KRAS mutation.<br /><br />The study utilized the CancerTYPE ID classifier, which is a gene expression-based classifier that can identify 50 different tumor types and subtypes for patients with CUP or unclear diagnoses. Additionally, multimodal biomarker testing including NGS, IHC, and FISH was used to identify actionable biomarkers that could guide targeted therapy selection.<br /><br />The researchers used a database called MOSAIC, which is an IRB-approved database of CUP and other unclear diagnoses. They found various tumor types with KRAS mutations in this database.<br /><br />The study identified specific tumor types in CUP and patients with unclear diagnoses who had actionable KRAS G12C mutations that would make them eligible for FDA-approved therapy. It was found that the identification of the tumor type is critical because the treatment regimens for KRAS inhibitors vary based on the specific tumor indication. This study supports the clinical utility of molecular tumor type classification by CancerTYPE ID coupled with biomarker profiling to identify additional treatment options for patients with CUP or unclear diagnoses.<br /><br />Overall, this study showed that integrating tumor type classification with molecular profiling can help identify patients with KRAS mutations who may be eligible for FDA-approved or investigational KRAS inhibitors, providing more treatment options for these patients.

Asset Subtitle

Thorvardur Halfdanarson

Keywords

molecular cancer classification

Next-Generation Sequencing

patients with cancer of unknown primary

KRAS inhibitors

non-small cell lung cancer

FDA-approved therapy

CancerTYPE ID classifier

multimodal biomarker testing

MOSAIC database

KRAS G12C mutations